Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
In May, irpagratinib received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). It is the first therapeutic agent to utilize molecularly defined biomarkers for precision-targeted treatment of HCC.
The vast majority of patients with advanced HCC treated with current standard-of-care therapies—including immune checkpoint inhibitors (ICIs) and multi-targeted kinase inhibitors (mTKIs)— experience disease progression within one year. Additionally, approximately 30% of HCC patients exhibit FGF19 overexpression, a biomarker associated with more aggressive tumor biology and poorer prognosis. The registrational study of irpagratinib (ABSK-011-205) is a multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of irpagratinib in combination with Best Supportive Care (BSC) versus placebo in combination with BSC, in patients with advanced or unresectable HCC who exhibit FGF19 overexpression and have previously been treated with ICIs and mTKIs. Eligible patients will be randomized in a 2:1 ratio to receive irpagratinib or placebo.
About Irpagratinib (ABSK-011)
Irpagratinib is a highly-selective FGFR4 small molecule inhibitor designed to target overexpression of the FGF19 signaling pathway. Several epidemiological studies indicate that approximately 30% of HCC patients worldwide exhibit FGF19 overexpression. Development of targeted therapies against FGFR4 represent an innovative and novel approach to the treatment of HCC.
To date, no FGFR4 inhibitor has been granted regulatory approval globally. According to Frost & Sullivan, irpagratinib is expected to become the first breakthrough treatment for the treatment of HCC patients with FGF19 overexpression.
In addition to monotherapy, Abbisko Therapeutics is exploring irpagratinib in combination with atezolizumab, an anti-PD-L1 antibody manufactured by F. Hoffmann-La Roche and Roche (China), in a Phase II study. At the previous 2024 ESMO GI Congress, Abbisko presented clinical data demonstrating 220mg irpagratinib BID in combination with atezolizumab achieved a 50% objective response rate (ORR) in FGF19+ HCC patients who had previously received immune checkpoint inhibition therapy.
About Abbisko Therapeutics
Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.
Please visit www.abbisko.com for more information.
View original content:https://www.prnewswire.com/news-releases/abbisko-therapeutics-completes-first-patient-dosing-in-registrational-study-of-irpagratinib-for-hcc-302481972.html
SOURCE Abbisko
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Aging Can Spread Through Your Body Via a Single Protein, Study Finds
Take note of the name: ReHMGB1. A new study pinpoints this protein as being able to spread the wear and tear that comes with time as it quietly travels through the bloodstream. This adds significantly to our understanding of aging. Short for reduced high mobility group box 1, ReHMGB1 triggers senescence in cells, permanently disabling them. It doesn't just do this locally; it can send damaging signals throughout the body, particularly in response to injuries or disease. "An important question in aging research is why senescent cells increase with age," write the study authors, led by researchers from the Korea University College of Medicine. Related: The team says their findings could help develop ways to keep us healthier for longer. If we can block or control this protein's signals, it might slow the cascade of cellular decline that comes with age. "This study reveals that aging signals are not confined to individual cells but can be systemically transmitted via the blood, with ReHMGB1 acting as a key driver," says Korea University biomedical engineer Ok Hee Jeon. The researchers were able to identify ReHMGB1 as a critical messenger passing on the senescence signal by analyzing different types of human cells grown in the lab and conducting a variety of tests on mice. When ReHMGB1 transmission was blocked in mice with muscle injuries, muscle regeneration happened more quickly, while the animals showed improved physical performance, fewer signs of cellular aging, and reduced systemic inflammation. The next step would be to see how this process could be disrupted, and this particular type of aging signal kept more localized – so the health conditions that come with old age might not be as damaging. "By blocking this pathway, we were able to restore tissue regenerative capacity, suggesting a promising strategy to treat aging-related diseases," says Jeon. This process is only one contributor to aging out of many, but the signals that ReHMGB1 spreads are particularly important in terms of our bodies becoming dysfunctional over time and less able to carry out repairs. It's also worth bearing in mind the useful functions of ReHMGB1 in the body: alerting our biological systems to damage and indicating that repairs are needed. Any kind of intervention will have to take that into consideration. We know that, generally speaking, populations are living for longer than ever before, and that's putting both our bodies and scientific research into uncharted territory. The various routines built into our cells must continue to function when years ago our bodies would have long given up. Related: From where we live to the genetics we're born with, there are many contributors to aging and lifespan. By learning more about how these work, we'll be better able to manage them – and perhaps extend life further. "Building on current research in these areas will be essential to understanding the therapeutic potential of redox-sensitive HMGB1 in aging-related diseases and its role as a systemic mediator of senescence," write the researchers in their published paper. The research has been published in Metabolism. Related News New Genetic Test Predicts Children With Future Risk of High BMI This Diet Helps Lower Dementia Risk, And We May Finally Know Why A Signal of Future Alzheimer's Could Hide in The Way You Speak Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
There's a Surprisingly Easy Way to Remove Microplastics in Your Drinking Water
Tiny fragments of plastics are making their way deep inside our bodies in concerning quantities, particularly through our food and drink. In 2024, scientists in China found a simple and effective means of removing them from water. The team ran tests on both soft water and hard tap water (which is richer in minerals). They added in nanoplastics and microplastics before boiling the liquid and then filtering out any precipitates. Related: "Tap water nano/microplastics (NMPs) escaping from centralized water treatment systems are of increasing global concern, because they pose potential health risks to humans via water consumption," the researchers from Guangzhou Medical University and Jinan University write in their published paper. In some cases, up to 90 percent of the NMPs were removed by the boiling and filtering process, though the effectiveness varied based on the type of water. Of course the big benefit is that most people can do it with what they already have in their kitchen. "This simple boiling water strategy can 'decontaminate' NMPs from household tap water and has the potential for harmlessly alleviating human intake of NMPs through water consumption," write biomedical engineer Zimin Yu from Guangzhou Medical University and colleagues. A greater concentration of NMPs was removed from samples of hard tap water, which naturally forms a buildup of limescale (or calcium carbonate) as it is heated. Commonly seen inside kitchen kettles, the chalky substance forms on the plastic's surface as changes in temperature force the calcium carbonate out of solution, effectively trapping the plastic fragments in a crust. "Our results showed that nanoplastic precipitation efficiency increased with increasing water hardness upon boiling," the team writes. "For example, from 34 percent at 80 mg L−1 to 84 percent and 90 percent at 180 and 300 mg L−1 of calcium carbonate, respectively." Even in soft water, where less calcium carbonate is dissolved, roughly a quarter of the NMPs were snagged from the water. Any bits of lime-encrusted plastic could then be removed through a simple filter like the stainless steel mesh used to strain tea, the researchers say. Past studies have measured fragments of polystyrene, polyethylene, polypropylene, and polyethylene terephthalate in potable tap water, which we're consuming daily in varying quantities. To put the strategy to the ultimate test, the researchers added even more nanoplastic particles, which were effectively reduced in number. "Drinking boiled water apparently is a viable long-term strategy for reducing global exposure to NMPs," write the researchers. "Drinking boiled water, however, is often regarded as a local tradition and prevails only in a few regions." The research team hopes that drinking boiled water might become a more widespread practice as plastics continue to take over the world. While it's still not certain exactly how damaging this plastic is to our bodies, it's clearly not the healthiest of snacks. Plastics have already been linked to changes in the gut microbiome and the body's antibiotic resistance. The team behind this latest study wants to see more research into how boiled water could keep artificial materials out of our bodies – and perhaps counter some of the alarming effects of microplastics that are emerging. "Our results have ratified a highly feasible strategy to reduce human NMP exposure and established the foundation for further investigations with a much larger number of samples," write the authors. The research has been published in Environmental Science & Technology Letters. An earlier version of this article was published in March 2024. Related News World First: Scientists Film The Exact Moment a Human Embryo Implants Chlorophyll & Collagen: Does Science Back TikTok's Favorite Supplements? Aging Can Spread Through Your Body Via a Single Protein, Study Finds Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
'It makes no sense to say there was only one origin of Homo sapiens': How the evolutionary record of Asia is complicating what we know about our species
When you buy through links on our articles, Future and its syndication partners may earn a commission. The story of our ancient ancestors began in Africa millions of years ago. But there are considerable gaps between the first and current chapters of that tale, and some anthropologists are looking to Asia to fill in missing information about how humans evolved. "The genus Homo evolved in Africa," Sheela Athreya, a biological anthropologist at Texas A&M University, told Live Science. But as soon as Homo left the continent, "all bets are off because evolution is going to treat every population differently." One bet Athreya is investigating is the notion that there wasn't a single origin of our species, Homo sapiens. Rather, the ancestors of today's humans living in different geographic regions took different evolutionary paths, before eventually coalescing into the human tribe we know today. Once humans left Africa, "you have so much complexity that it makes no sense to say there was only one origin of Homo sapiens," Athreya said. Key to this story is a different understanding of human evolution in Asia — and the possibility that Denisovans, a group of little-understood extinct human ancestors known from just a handful of fossils, were actually the same as a much earlier member of our family tree: Homo erectus, Athreya argues. Related: Strange, 300,000-year-old jawbone unearthed in China may come from vanished human lineage Early humans in ancient Asia There's a big gap in human evolutionary history. We know Homo evolved in Africa and that a human ancestor, Homo erectus, was already in Asia and parts of Europe by about 1.8 million years ago. But what happened in Asia between that point and the time when Homo sapiens arrived around 50,000 years ago? That picture is much less clear. To help fill it in, Athreya has considered the emergence of our species, Homo sapiens, during the Middle and Late Pleistocene epoch (780,000 to 11,700 years ago). Her "deep-dive" into the human fossil record of Asia has convinced her that there are evolutionary pathways in places like Java, Indonesia, that differ from the Pleistocene patterns seen in Africa and Europe. H. erectus reached Java at least 1.5 million years ago, and the species likely lasted there until 108,000 years ago. But the lack of more recent H. erectus bones doesn't necessarily mean they went extinct, Athreya wrote in a 2024 study with co-author Yousuke Kaifu, an anthropologist at the University of Tokyo. Instead, these Javanese H. erectus could have persisted until H. sapiens appeared in Sumatra as early as 73,000 years ago and interbred with them. The fossil record in China is similarly complicated. Around 300,000 years ago, there was a shift in what H. erectus fossils looked like, Athreya said. Skeletons in the Middle Pleistocene in China became more variable in form, and traits that were common in Western Eurasian groups like H. sapiens and Neanderthals, such as smoother bicuspid teeth, began to appear in these fossils. This means that — instead of completely dying out — H. erectus in China may have made a genetic contribution to populations living today, Athreya said, just as Neanderthals left genetic traces in people with European ancestry and Denisovans contributed DNA to people with Oceania ancestry. The idea isn't impossible, one expert told Live Science. Groups of ancient human relatives could have mated anywhere they met up, Adam Van Arsdale, a biological anthropologist at Wellesley College in Massachusetts, told Live Science. No matter where they lived, "I just think humans aren't that different" during the Pleistocene. What's more, anthropologists are starting to realize that many of these groups that looked very different could still have interbred. Twenty years ago, scientists would have said "there's no possible way" they could have interbred, Van Arsdale said. "And I just don't think we can assume that anymore." So far, no DNA has been recovered from H. erectus fossils, largely because most of their fossils are too old, so there's no genetic support for this idea. But emerging methods for extracting ancient proteins from fossils may soon make it feasible to identify some H. erectus genes. Another route to understanding the fate of H. erectus in Asia may be to look more closely at the enigmatic Denisovans. RELATED STORIES —Oldest wooden tools unearthed in East Asia show that ancient humans made planned trips to dig up edible plants —Ancient jawbone dredged off Taiwan seafloor belongs to mysterious Denisovan, study finds —140,000 year old bones of our ancient ancestors found on sea floor, revealing secrets of extinct human species Since the only known skull of a Denisovan looks similar, in many ways, to that of H. erectus, those two groups may actually be one and the same. "I don't think that genetics is going to find that Homo erectus was a separate dead-end lineage," Athreya said. "I would expect Denisovans to be Homo erectus." But until more work is done that combines DNA, artifacts and fossil bones in Southeast Asia, the full picture of human evolution cannot yet come into focus the way it has in places like Europe, Athreya said. Human evolution quiz: What do you know about Homo sapiens?
